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Abstract                                                     
Methoxyflurane was developed as an anaesthetic agent and introduced into clinical practice 
in 1960. It soon became evident that it possessed analgesic properties that other drugs did not. 
Due to toxicity concerns, it lost favour in general anaesthesia and had been largely abandoned 
by the late 1970's. The manufacturer withdrew it in 1999, and the Food and Drug 
Administration in the United States did not renew its license in 2005. It has also been 
withdrawn by the European Union. However, it continues to be used in Australasia, primarily 
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trauma. It has become attractive for use in dental practice, likely due to its effectiveness as an 
analgesic and its additional sedative qualities. Its acceptance is controversial as its use in 
dentistry is largely elective.  Despite its good safety record in analgesic doses, adverse 
reactions have been recorded.  Practitioners should be well aware of risks associated with its 
use before considering administration, and carefully assess whether or not there are equally 
good alternative options that do not the carry the same risks.  Methoxyflurane is reviewed 
below with an emphasis on its use in dental practice. 
 
Keywords: analgesic, dentistry, inhalation, Methoxyflurane, safety 
 
Background 
The principle for methoxyflurane development initially occurred when methyl alcohol was 
added to Fluoroethylenes.1 Described as the first "modern" halogenated ether, it was 
introduced in 1959,2 and clinical evaluation in 100 patients was reported in 1960.3 It was 
described as a second-generation halogenated inhaled anaesthetic but was withdrawn from 
use in many countries due to case reports of renal impairment.4 Its use in anaesthetics 
declined in the 1970's due to adverse effects.  Despite this, it continued to be used in some 
parts of the world as a self-administered inhalational preparation, for example “the 
Analgizer”.5  In 1999, the manufacturers, Abbott Laboratories, voluntarily withdrew 
methoxyflurane from US market. FDA later revoked its license in 2005. However, it remains 
licensed for use in Australia (Therapeutic Goods Administration) and New Zealand 
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The analgesic qualities of methoxyflurane were recognised shortly after its introduction for 
clinical use,6 and this view was supported a few years later.7  An assessment of six inhalation 
anaesthetic agents used at sub-anaesthetic concentrations found that methoxyflurane and 
nitrous oxide possessed both analgesic and hypnotic actions, which halothane, enflurane, 
isoflurane and sevoflurane did not.8 A role for methoxyflurane was suggested in situations 
where general anaesthesia was a significant hazard or regional anaesthesia was deemed 
impractical or contraindicated.9  In a small cohort pilot study, in children, it was deemed 
effective as an analgesic, with no serious adverse events, and found most useful as a bridging 
analgesic agent post extremity trauma.10  Methoxyflurane as a Penthrox (Medical 
Developments International, Springvale, Victoria, Australia) inhaler was approved under the 
PBS for prescription by medical practitioners.11,12  
 
Pharmacology 
Methoxyflurane is 2,2-dichloro-1,1-difluoro-ethyl methyl ether. It is a clear, almost 
colourless liquid with a characteristic odour. At its recommended concentrations, it is non-
flammable and chemically stable in the presence of light, oxygen, moisture and carbon 
dioxide absorbents. Methoxyflurane vapour provides analgesia when inhaled at low 
concentrations. Once absorbed, 50-70% is metabolized to free fluoride, oxalic acid, 
difluoromethoxyacetic acid, and dichloroacetic acid.  The high blood gas partition coefficient 
of methoxyflurane was found to be of considerable benefit ensuring pain relief for a 
prolonged period after administration was ceased.13 Its propensity to diffuse into fatty tissues 
creates a slow release reservoir for days post administration.14 This is of particular concern in 
the dental setting as many anxious patients may also be obese and if they are promptly 
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Clinical Use 
The pre-hospital setting: 
Methoxyflurane is as a self administered inhalational analgesic in pre-hospital settings in 
which the patient is intentioned towards a full medical service and primary attention is 
allocated to monitor and assist the sedated patient.  Although there are no published 
controlled trials of use of methoxyflurane in sub-anaesthetic doses, available data suggests 
that it is effective as an analgesic, particularly in the pre-hospital post-trauma setting15-17 with 
its strength lying in the rapidity of pain relief onset.18 This facilitates patient comfort prior to 
treatment in a hospital setting where more potent intravenous medications can be 
administered by personnel with appropriate training with the availability of monitoring and 
resuscitation facilities. It is, however, reported to be less effective in overall pain relief than 
fentanyl and morphine in both adults and children.19 20 Further, there is insufficient 
information to support its use for procedural pain. 21 The incidence of adverse events has 
been reported in the literature as low/insignificant when the recommended doses are not 
exceeded, although deep sedation has been reported in children less than five years old.16,21 
Aside from trials of its use in pre-hospital settings, there has been minimal data on the use of 
methoxyflurane in the last 30 years.  
Dressings for burns: 
Methoxyflurane was found to be useful as an analgesic for burns' dressings.22,23 
Patient acceptance was good, and advantages included no undue sedation, no need for 
preoperative starvation, and venepuncture being avoided.  Use in burn dressings for children 
has been variably reported, with one study of patients under five years reporting that it 
provided unsatisfactory analgesia,24 while a separate study25 reported that analgesia was 
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Obstetric practice: 
Methoxyflurane was used extensively in obstetric practice when it became initially available. 
It was described as drug of choice in obstetric anaesthesia.26 A review of 645 cases in 1962 
found methoxyflurane to be a safe anaesthetic and analgesic agent, without side-effects, 
because only low concentrations were needed.27 When self-administered, methoxyflurane 
was deemed a more effective analgesic, with less nausea and vomiting, when compared to 
nitrous oxide,28 and another study found in the same year (1969) methoxyflurane similarly 
satisfactory, noting there were no ill effects upon the foetus.29 Pain relief was reported up to 
36-48 hours post-partum but also some drowsiness.30 It was suggested that there was no 
evidence of renal dysfunction after self-administered use during labour.31 However, a 
subsequent study in 1977 reported dose dependent changes in renal markers of both mothers 
and neonates.32  Methoxyflurane is no longer a drug of use in obstetric practice.  
 
Dental practice: 
The use of methoxyflurane in dentistry was recommended due to its analgesic and sedative 
properties.33 Safety and simplicity of administration were noted in two other reports.34,35   An 
early (1960) blinded trial on methoxyflurane in dental anaesthesia did not demonstrate any 
particular advantage in its use.38   A study from 1975 showed that nitrous oxide caused 
significantly less uncooperative behaviour than methoxyflurane.36   In a recent study, the 
Penthrox inhaler provided comparable sedation to nitrous oxide when third molars were 
removed under local anaesthesia. 37 This study was completed on a group of healthy 
individuals aged between 18-30 in an oral and maxillofacial clinic with full resuscitation 
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Adverse effects 
In the 1960s, an emphasis on development of improved analgesics and anaesthetic drugs saw 
published data on fluorinated anaesthetic compounds, initially predominantly animal 
studies,39-42 and proceeding into human clinical trials.43,44  The results from one large series 
was encouraging,45 with the main adverse effect in most reports appearing to be respiratory 
depression. As discussed above, methoxyflurane has a propensity to diffuse into fatty tissues 
creating a slow release reservoir for days post administration.14 In the dental setting, if used 




Changes in renal function, and the potential for nephrotoxicity, were being monitored if not at 
the time of, then shortly after, the introduction of methoxyflurane into clinical practice.46-48 
Limitations on concentration and duration of exposure were suggested.49 Deaths due to renal 
failure at analgesic doses via a penthrane analgiser have also been reported.50   The 
mechanism of renal toxicity of methoxyflurane is unknown. There has been a suggested role 
of intrarenal generation of nephrotoxic metabolites, in particular inorganic fluoride ions.51 
More recently a new hypothesis of methoxyflurane nephrotoxicity proposed that it may result 
from O-demethylation which forms both fluoride and dichloroacetic acid.52  The formation of 
the two compounds is unique to methoxyflurane compared to other volatile anaesthetics. 
 
An earlier laboratory study in rats suggested that the predominant factors leading to 
methoxyflurane nephrotoxicity appeared to be dosage of the agent, and serum inorganic 
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metabolism, sensitivity of the kidney to inorganic fluoride toxicity, concurrent treatment with 
other nephrotoxic drugs, pre-existing renal disease, repeat administration, and concurrent 
treatment with enzyme-inducing drugs such as phenobarbital.53 
 
Hepatotoxicity 
There have been a number of reports of hepatotoxicity, some non-fatal54-57 and some fatal.58-
60
   Repeated exposure,61 even in sub-anaesthetic concentrations,62 may be a risk factor. One 
conclusion drawn in a further report of two obstetric cases was that idiosyncratic hepatitis 
will continue to occur unpredictably in a very few patients.63 In 2008, a review of adverse 
drug reactions with halogenated anaesthetics, focused on adverse organ effects (including 
hepatic and renal) that were attributable to anaesthetic metabolism and/or degradation. It was 
stated that none of the currently available halogenated anaesthetics cause clinically 
significant changes in renal function2 but the licence for the use of methoxyflurane had been 
withdrawn64 in the USA by the time this article was published. A manufacturer-funded study 
(which indicated there was no conflict of interest) found no difference in event rates for 
cardiac/renal/hepatic/disease plus diabetes and cancer, between those who received 
Methoxyflurane, and those who did not, in the pre-hospital setting.65 
 
Illicit use and occupational hazards 
There are a number of papers documenting diverse medical problems as a result of 
methoxyflurane abuse: renal57, psychiatric66, multisystem67, and ocular.68 Attention to the 
potential for occupational hazards for anaesthetists was drawn,69 and rare but significant 
occupational exposure problems have been reported including hepatic and renal effects; 
specifically, these were significantly elevated levels of blood urea nitrogen, serum uric acid, 
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transaminases (SGPT) three days after exposure to Methoxyflurane, emphasising the need for 
good scavenging.32  Exacerbation of subclinical myasthenia (reversible lethargy, muscular 
weakness and ptosis) in a nurse anaesthetist has also been reported.70  
 
Access and Availability of Information 
Availability of methoxyflurane is not limited to ambulance and Emergency Department but 
available for purchase by health professionals.  According to an Australian manufacturer’s 
website, it can be purchased by a dentist with provision of a “Dental Registration 
Certificate/Card”. 71 The available product information guide contains comprehensive 
information. 72 Contraindications include patients with renal impairment and failure, 
hypersensitivity to fluorinated anaesthetics, cardiovascular instability, respiratory depression, 
head injury or loss of consciousness.  Caution is highlighted for those with liver disease and 
diabetes, the elderly and the obese and patients on enzyme inducing drugs.  Additionally, 
health care workers regularly exposed to patient using methoxyflurane inhalers are 
encouraged to be aware of relevant occupation health and safety guidelines for use of 
inhalational agents.  Dental use is analogous to other usages. The maximum stated daily dose 
of 2 bottles x 3ml and no more than 15ml (5 bottles) in a week for all patients. Regarding 
operation of a vehicle after administration, this is suggested to be at the discretion of the 
treating doctor, however a minimum of 24 hours would seem prudent. 72   
  
Guidelines for the use of methoxyflurane in Dental Practice 
1.   Safety in the use of methoxyflurane can only be possible if used in accordance with the 
manufacturer’s instructions and anxiolysis guidelines of the Dental Board of Australia. A 










This article is protected by copyright. All rights reserved. 
2.   Although the product is readily available, it should be known that the use of 
methoxyflurane is governed under the anxiolysis guidelines of the Dental Board of Australia.  
There is a clear requirement for training on the correct use of methoxyflurane with the need 
for oxygen, airway management skills and life support skills. 
3. Patient selection requires that a full and current patient medical history be taken by the 
clinician with particular relevance to strict and relative contraindications.  
4. Prior to use, dentists should carefully consider whether or not there are alternatives to 
methoxyflurane that do not carry the same risk of adverse reactions.   
5. Should the procedure require anything more than simple anxiolysis or analgesia, 
methoxyflurane is not indicated, and the patient should be referred. 
6. A clear and concise discussion on its intended use should be had with the patient prior to 
its use. This should not occur at the same appointment that this is intending to be used. 
7. Methoxyflurane should not be used with any other sedative medication, as it is likely that 
this will be both harmful and illegal if dentist is not an endorsed Dental Sedationists. 
8. Extreme care should be taken to not allow misuse of methoxyflurane. It is not appropriate 
to override patient control by holding the device to the patient’s mouth during administration. 
9. Patients should be monitored after administration of methoxyflurane and should not 
operate machinery or drive a vehicle until they have completely recovered from the effects of 
the drug, and it is recommended that this be at least 24 hours.  
10. Dentists and patients must be well informed of the possibility of developing late 
complication.   
11. Similar to that recommended for the use of methoxyflurane in the ambulance setting to 
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administer more than two doses of methoxyflurane in any given day. 
 
Conclusions on use in dentistry 
Adverse effects are rare when Methoxyflurane is administered in analgesic doses. However 
its legitimate role and limitations in the dental surgery are unclear.  There is a lack of recent 
and well-designed studies describing or supporting its use in routine dental practice.  
Practitioners, at a minimum, must be aware of the risks of this drug to their patients, their 
staff and themselves. Current regulations for the use of inhalational sedatives used in 
dentistry call for formalized training of the practitioner and the requirement of appropriate 
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